Drug intelligence / Profile preview

ALK Avanz

Development stage: Unknown
Lead developer: ALK Abelló
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ALK Avanz is an allergen extract developed by ALK-Abelló for subcutaneous allergen-specific immunotherapy (SCIT). It is used to treat seasonal allergic rhinoconjunctivitis, particularly that induced by grass pollen allergens. The drug functions as an immunomodulator, aiming to desensitize the immune system to specific allergens and reduce allergic reactions.

Brand names: AvanzAVANZ Phleum pratense
Other names: Grass pollen allergy immunotherapy low dose - ALK-AbelloGrass pollen allergy vaccine - ALK-Abello

Beyond the preview

Go deeper on ALK Avanz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALK Avanz.

Explore the full profile